Dr. Young on Eltrombopag Added to Immunosuppression for Patients With Aplastic Anemia
Neal Young, MD, senior investigator, Cell Biology Section, National Heart, Lung, and Blood Institute, National Institute of Health, discusses a study that examined the efficacy of eltrombopag when added to standard immunosuppression for patients with aplastic anemia.
Neal Young, MD, senior investigator, Cell Biology Section, National Heart, Lung, and Blood Institute, National Institute of Health, discusses a study that examined the efficacy of eltrombopag when added to standard immunosuppression for patients with aplastic anemia.
In this phase II study, 92 patients were accrued. Results showed an increase in immunologic response rate, robust blood cell counts, and an improvement in survival. There was one patient death on the study, Young adds.
These results suggest that the immediate addition of eltrombopag with standard immunosuppression may salvage and expand residual hematopoietic stem cells in aplastic anemia.
<<<
